AstraZeneca’s Soliris Wins EU Recommendation In Pediatric gMG As Competition Looms
Addressing Unmet Need
The UK major’s older C5 inhibitor product could soon receive EU approval for children and adolescents with the rare disease, but emerging competition from biosimilar developers and rival firms are starting to stack up.
